XNAS
SIGA
Market cap240mUSD
Oct 08, Last price
3.28USD
1D
0.61%
1Q
-8.64%
Jan 2017
13.89%
Name
SIGA Technologies Inc
Chart & performance
P/E
10.10
P/S
2.49
EPS
0.32
Div yield, %
17.91%
Shrs. gr., 5y
-2.05%
Rev. gr., 5y
-5.41%
Revenues
95m
-31.80%
Net income
23m
-60.65%
CFO
43m
-10.85%
Dividend
Apr 07, 20260.6 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
SIGA Technologies, Inc. is a pharmaceutical company with commercialized products, specializing in the health security and infectious disease sectors across the United States. A core offering is TPOXX, an oral antiviral drug formulated to combat human smallpox, a condition caused by the variola virus. Furthermore, the company has forged a strategic collaboration with Cipla Therapeutics. This partnership aims to ensure ongoing innovation and accessibility of antibacterial treatments, particularly those designed to counter biothreats. Founded in 1995, SIGA Technologies' corporate headquarters are located in New York, New York.
Key people
Dennis Hruby
Executive Vice President, Chief Scientific Officer · since 2021
Lawrence Miller
General Counsel · since 2024
Daniel Luckshire
Chief Financial Officer, Executive Vice President, Corporate Secretary · since 2011
Evan Knisely
Director · since 2023
Chief Executive Officer, Director · since 2024
Jaymie Durnan
Independent Director · since 2020
Harold Ford
Independent Director · since 2022
John Keane
Independent Director · since 2025
Independent Director · since 2009
Gary Nabel
Independent Director · since 2021
Independent Director · since 2020
Holly Phillips
Independent Director · since 2021
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||